Prospective data that assesses the impact of degree of acute fluid overload and/or blood pressure variations, incidence and significance of arrhythmias, pericardial effusions as well as the role of potential biomarkers such as brain natriuretic peptide (BNP) and galectin-3, with regard to post-HCT outcomes may inform future monitoring and management strategies (29, 30). This evidence concerns the gene NPPB and pericardial effusion.